Guerbet Looks To Separate Dotarem In Crowded Contrast Agent Market
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory committee scheduled for Valentine’s Day is key test for Guerbet’s efforts to get its MRI imaging agent a wider indication than Bayer’s Gadavist.